AOCNP Clinical Trials and Evidence-Based Oncology Practice 1 — Questions and Answers
Question 1: In a Phase I clinical trial for a new oncology drug, the primary objective is to determine:
- Efficacy and overall response rate
- Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) (Correct answer)
- Long-term survival benefit compared to standard of care
- Quality of life improvements over existing therapy
Correct answer: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs)
Phase I trials are primarily safety/dose-finding studies. The primary objectives are to establish the maximum tolerated dose (MTD), characterize dose-limiting toxicities (DLTs), determine the recommended Phase II dose (RP2D), and describe the pharmacokinetic profile. Efficacy is a secondary/exploratory endpoint.
Question 2: The principle of equipoise in clinical trial ethics means:
- All participants must receive the same treatment
- There is genuine uncertainty about which treatment arm is superior, justifying randomization (Correct answer)
- Participants must be equally distributed across age groups
- The trial must include equal numbers of males and females
Correct answer: There is genuine uncertainty about which treatment arm is superior, justifying randomization
Clinical equipoise means there is genuine scientific uncertainty in the expert medical community about which treatment is superior. Equipoise is the ethical justification for randomizing patients — if one treatment is clearly superior, randomization would be unethical. When evidence tips decisively in one direction, trials are stopped by data safety monitoring boards.
Question 3: Informed consent for clinical trial participation must include which elements specific to research, beyond standard clinical care consent?
- Only the principal investigator's contact information
- Voluntary nature of participation, right to withdraw, foreseeable risks/benefits, and availability of alternative treatments (Correct answer)
- Guarantee of treatment benefit based on Phase I data
- Insurance billing codes for the experimental intervention
Correct answer: Voluntary nature of participation, right to withdraw, foreseeable risks/benefits, and availability of alternative treatments
Research informed consent must include (per 45 CFR 46 and ICH-GCP): a statement that the study involves research, foreseeable risks and benefits, alternative procedures, confidentiality protections, compensation for injury, contact information, and explicit statement that participation is voluntary with the right to withdraw without penalty.
Question 4: A randomized controlled trial (RCT) in oncology is considered the gold standard for evidence because:
- It is faster and less expensive than observational studies
- Randomization controls for confounding variables and reduces selection bias, allowing causal inference (Correct answer)
- All patients receive the experimental treatment
- RCTs always include placebo control arms
Correct answer: Randomization controls for confounding variables and reduces selection bias, allowing causal inference
The RCT is the gold standard because random allocation to treatment and control groups balances known and unknown confounders, minimizing selection bias. This allows valid causal inference about treatment effects. Blinding further controls for performance and detection bias.
Question 5: Which term describes a trial design where a new agent is tested across multiple cancer types based on a shared molecular target (biomarker) rather than tumor histology?
- Umbrella trial
- Basket trial (Correct answer)
- Platform trial
- Crossover trial
Correct answer: Basket trial
Basket trials (also called histology-agnostic or tumor-agnostic trials) enroll patients across different tumor types that share a specific molecular alteration (e.g., NTRK fusion, MSI-H, BRAF V600E), testing whether a targeted therapy works regardless of tissue of origin. Examples: larotrectinib (NTRK), pembrolizumab (MSI-H).
Question 6: The ONCO NP role in clinical trials includes which key responsibility?
- Designing the statistical analysis plan for the trial
- Ensuring protocol adherence, obtaining informed consent, monitoring for adverse events, and educating patients about trial participation (Correct answer)
- Determining eligibility criteria independently without PI oversight
- Unblinding participants when they request it
Correct answer: Ensuring protocol adherence, obtaining informed consent, monitoring for adverse events, and educating patients about trial participation
Advanced practice oncology nurses in clinical research play critical roles: patient education about trial procedures and expectations, obtaining/witnessing informed consent, accurate data collection, toxicity monitoring per protocol, dose modification implementation, adverse event reporting, and serving as patient advocates and primary contact throughout the trial.
AOCNP Clinical Trials and Evidence-Based Oncology Practice 1
In a Phase I clinical trial for a new oncology drug, the primary objective is to determine: